Pfizer Cash Flow Statement
PFE / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Pfizer generated $11.7B in operating cash flow and $9.1B in free cash flow in FY2025. Free cash flow margin was 14.5% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.09 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $7.8B | $8.0B | $22.0B | $9.2B | $16.0B | $9.2B | $16.0B | $7.2B | $7.0B | $9.1B | $7.0B | $9.1B | $10.0B | $8.3B | $10.0B |
| Depreciation & Amortization | $6.6B | $7.0B | $5.2B | $4.7B | $5.8B | $4.7B | $5.8B | $5.8B | $5.2B | $5.5B | $5.2B | $5.5B | $8.7B | $8.4B | $8.7B |
| Operating Cash Flow | $11.7B | $12.7B | $32.6B | $14.4B | $12.6B | $14.4B | $12.6B | $16.2B | $14.7B | $17.1B | $14.7B | $17.1B | $20.2B | $11.5B | $20.2B |
| Capital Expenditures | $2.6B | $2.9B | $2.7B | $2.2B | $2.0B | $2.2B | $2.0B | $1.8B | $1.4B | $1.2B | $1.4B | $1.2B | $1.7B | $1.5B | $1.7B |
| Free Cash Flow | $9.1B | $9.8B | $29.9B | $12.2B | $10.5B | $12.2B | $10.5B | $14.4B | $13.3B | $15.9B | $13.3B | $15.9B | $18.6B | $9.9B | $18.6B |
| Share Buybacks | - | $0 | $0 | $0 | $8.9B | $0 | $8.9B | $5.0B | $5.2B | $5.0B | $5.2B | $5.0B | $9.0B | $1.0B | $9.0B |
| Dividends Paid | - | - | $8.7B | $8.4B | $8.0B | - | - | $7.3B | $6.9B | $6.6B | - | - | $6.2B | $6.1B | - |
| FCF Margin | 14.5% | 15.5% | 36.7% | 29.2% | 25.8% | 29.2% | 25.8% | 27.2% | 27.2% | 32.0% | 27.2% | 32.0% | 30.4% | 15.3% | 30.4% |